Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Common Equity (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Common Equity for 12 consecutive years, with $5.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 46.37% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Sep 2025, down 46.37%, and an annual FY2024 reading of $6.2 million, down 51.01% over the prior year.
  • Common Equity was $5.4 million for Q3 2025 at Arcadia Biosciences, up from $4.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $45.7 million in Q1 2021 and bottomed at $4.5 million in Q2 2025.
  • Average Common Equity over 5 years is $20.1 million, with a median of $16.7 million recorded in 2023.
  • The sharpest move saw Common Equity surged 273.91% in 2021, then crashed 60.81% in 2025.
  • Year by year, Common Equity stood at $31.2 million in 2021, then tumbled by 33.0% to $20.9 million in 2022, then crashed by 39.22% to $12.7 million in 2023, then crashed by 51.01% to $6.2 million in 2024, then fell by 12.53% to $5.4 million in 2025.
  • Business Quant data shows Common Equity for RKDA at $5.4 million in Q3 2025, $4.5 million in Q2 2025, and $8.9 million in Q1 2025.